Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A8MD
|
|||
| Former ID |
DNC002522
|
|||
| Drug Name |
2-HYDROXY-3,5-DIIODOBENZOIC ACID
|
|||
| Synonyms |
3,5-DIIODOSALICYLIC ACID; 133-91-5; 2-Hydroxy-3,5-diiodobenzoic acid; 3,5-Diiodo-2-hydroxybenzoic acid; Benzoic acid, 2-hydroxy-3,5-diiodo-; 2-Hydroxy-3,5-diiodobenzoate; 3,5-Diiodosalicylate; 2-Hydroxy-3,5-diiodobenzenecarboxylic acid; 2-HYDROXY-3,5-DIIODO-BENZOIC ACID; Salicylic acid, 3,5-diiodo-; NSC 6303; Benzoic acid, 3,5-diiodo-2-hydroxy-; UNII-1496OH15B6; 3,5-Diiodosalicylicacid; EINECS 205-124-0; BRN 2615358; AI3-33355; NSC6303; DHZVWQPHNWDCFS-UHFFFAOYSA-N; MFCD00002444; 1496OH15B6; DIU; rarechem al be 0656; ACMC-1BPSO
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H4I2O3
|
|||
| Canonical SMILES |
C1=C(C=C(C(=C1C(=O)O)O)I)I
|
|||
| InChI |
1S/C7H4I2O3/c8-3-1-4(7(11)12)6(10)5(9)2-3/h1-2,10H,(H,11,12)
|
|||
| InChIKey |
DHZVWQPHNWDCFS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 133-91-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
72292, 607492, 3132925, 4389280, 7887056, 8001989, 8027948, 8156100, 10506878, 15004752, 24893385, 29227299, 46504394, 46507861, 49830812, 50045253, 50365425, 56367325, 57325142, 57939281, 85085480, 85247016, 87568153, 88683727, 92710266, 103119197, 104248422, 104318355, 105596734, 117512023, 118560201, 125340212, 126546855, 126632044, 126688027, 127737700, 130935160, 134974765, 134980661, 137021197, 140219105, 143454025, 144024740, 160787096, 160967661, 162176777, 162271333, 163304611, 163371123, 163726658
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endothelin A receptor (EDNRA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Endothelin signaling pathway | |||
| Pathway Interaction Database | Endothelins | |||
| EGFR-dependent Endothelin signaling events | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Allosteric inhibition of endothelin ETA receptors by 3, 5-dibromosalicylic acid. Mol Pharmacol. 2000 Dec;58(6):1461-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.